PBC Biomed Appoints Mark McMahan as Chief Commercial Officer [Yahoo! Finance]
Smith & Nephew SNATS, Inc. (SNN)
Last smith & nephew snats, inc. earnings: 8/1 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
smithoptics.com
Company Research
Source: Yahoo! Finance
appointment of Mark McMahan as Chief Commercial Officer, effective October 2025. McMahan, formerly Vice President of Global & US Trauma & Extremities Marketing at Smith & Nephew, brings extensive international expertise in medical device commercialization and strategy. In his new role, McMahan will oversee global commercialization strategies for PBC Biomed's proprietary technologies, including OsStic® bioadhesive, ARC, and VAPS. He will also lead commercial planning for client products, such as the ReFeel™ nerve repair solution, supporting the company's expanding portfolio of innovative medical technologies. Paul Burke, Managing Partner at PBC Biomed, commented: “This announcement reflects PBC Biomed's commitment to advancing our global presence and building strong commercial pathways for our technologies and client products. Mark's experience and leadership will be invaluable as we continue to scale and deliver transformative solutions in the medical device space.” Mark McMah
Show less
Read more
Impact Snapshot
Event Time:
SNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNN alerts
High impacting Smith & Nephew SNATS, Inc. news events
Weekly update
A roundup of the hottest topics
SNN
News
- Smith & Nephew plc (LON:SN.) is favoured by institutional owners who hold 88% of the company [Yahoo! Finance]Yahoo! Finance
- Read the ruling [The New York Times]The New York Times
- Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Kepler Capital Markets to a "strong-buy" rating.MarketBeat
- Smith & Nephew SNATS (NYSE:SNN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $34.00. They now have a "hold" rating on the stock.MarketBeat
- Smith+Nephew comparative study1 shows PICO? sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWTGlobeNewswire
SNN
Sec Filings
- 12/1/25 - Form 6-K
- 11/19/25 - Form 6-K
- 11/18/25 - Form 6-K
- SNN's page on the SEC website